Literature DB >> 14514743

Impairment of transendothelial leukocyte migration by iron complexes.

Gürkan Sengoelge1, Josef Kletzmayr, Ilse Ferrara, Agnes Perschl, Walter H Hörl, Gere Sunder-Plassmann.   

Abstract

Although iron sucrose and iron gluconate are generally well tolerated in patients who are treated for renal anemia, recent clinical studies and cell culture experiments suggested significant toxicity and long-term side effects arising from the use of these iron complexes. Because of the possible role of iron in infection or cardiovascular disease, it was theorized that parenteral iron compounds influence endothelial and PMN interaction in vitro. A well-established double-chamber method was used to assess the effect of different concentrations of iron sucrose and iron gluconate (1, 25, 50, and 100 micro g/ml) on the transendothelial migration of PMN. Preincubation of PMN and endothelial cells as well as preincubation of PMN alone with 25, 50, or 100 micro g/ml iron resulted in a significant decrease in PMN migration. In contrast, after incubation of the endothelial cells alone with iron, no reduction in the transendothelial migration of PMN was observed. Preincubation of PMN and/or endothelial cells with 1 micro g/ml iron did not lead to any decrease in the rate of migrated PMN. The only significant change in experiments with 1 micro g/ml was an increase in PMN migration after preincubation of endothelial cells and PMN with iron gluconate. A four-way ANOVA showed a significant effect of the iron concentration (P < 0.000001), of type of iron complex (P < 0.005), of the preincubation of endothelial cell (P < 0.001), and of the preincubation of PMN with iron (P < 0.000001) on PMN diapedesis. It is concluded that iron sucrose and iron gluconate cause a significant inhibition of transendothelial migration of PMN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514743     DOI: 10.1097/01.asn.0000087087.61306.4a

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  12 in total

1.  Chronic use of oral iron supplements is associated with poor clinical outcomes in patients with gram-negative bacteremia.

Authors:  Alaa Atamna; Hani Hamud; Waseem Daud; Tzippy Shochat; Jihad Bishara; Avishay Elis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-26       Impact factor: 3.267

2.  Anaemia: FIND-CKD: intravenous iron in predialysis CKD.

Authors:  Steven Fishbane; Azzour D Hazzan
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

Review 3.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

4.  Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients.

Authors:  Hassan N Ibrahim; Robert N Foley; Rui Zhang; David T Gilbertson; Allan J Collins
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

Review 5.  Safety issues with intravenous iron products in the management of anemia in chronic kidney disease.

Authors:  Amir Hayat
Journal:  Clin Med Res       Date:  2008-12

6.  Hfe deficiency impairs pulmonary neutrophil recruitment in response to inflammation.

Authors:  Karolina Benesova; Maja Vujić Spasić; Sebastian M Schaefer; Jens Stolte; Tomi Baehr-Ivacevic; Katharina Waldow; Zhe Zhou; Ursula Klingmueller; Vladimir Benes; Marcus A Mall; Martina U Muckenthaler
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

Review 7.  Iron therapy for renal anemia: how much needed, how much harmful?

Authors:  Walter H Hörl
Journal:  Pediatr Nephrol       Date:  2007-01-06       Impact factor: 3.714

8.  A randomized trial of intravenous and oral iron in chronic kidney disease.

Authors:  Rajiv Agarwal; John W Kusek; Maria K Pappas
Journal:  Kidney Int       Date:  2015-06-17       Impact factor: 10.612

9.  Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Yao-Ping Lin; Ching-Fang Tang; Tzong-Shyuan Lee; Chih-Pei Lin; Der-Cherng Tarng
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

10.  High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats.

Authors:  Eva Gravesen; Jacob Hofman-Bang; Maria L Mace; Ewa Lewin; Klaus Olgaard
Journal:  BMC Nephrol       Date:  2013-12-27       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.